Accurate Education - PEA for Chronic Pain: A Patient Guide

Nutraceuticas:

PEA (Palmitoylethanolamide) for Chronic Pain: A Patient Guide

Palmitoylethanolamide (PEA) is a natural compound that our bodies produces on demand in response to tissue injury and inflammation as part of our body’s own protective system against damage and pain.

See:

Nutraceutical patient Guides:

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

Palmitoylethanolamide (PEA) for Chronic Pain: A Patient Guide

1. OVERVIEW

PEA is effective and well-tolerated, used for managing chronic, neuropathic, and inflammatory pain, with studies showing significant pain reduction within 4–6 weeks. It works by modulating immune responses, reducing neuroinflammation, and interacting with receptors in the body.

What makes PEA valuable for chronic pain:

Modulates the endocannabinoid system without directly binding to cannabinoid receptors (no psychoactive effects)
Down-regulates mast cell activation—key immune cells involved in inflammation and pain
Controls glial cell behavior in the brain and spinal cord, reducing neuroinflammation
Activates PPAR-α (peroxisome proliferator-activated receptor alpha), a master regulator of inflammation
Provides neuroprotection and supports nerve health
Has an excellent safety profile with no significant drug interactions[1][3]

How PEA Compares to Conventional Medications:

A 2025 meta-analysis of 18 randomized clinical trials (1,196 patients) found that PEA significantly reduces pain across all pain types—nociceptive, neuropathic, and nociplastic—with benefits observed within 4–6 weeks of treatment.[1] A 2023 systematic review and meta-analysis found PEA reduced pain scores with a large effect size (SMD = 1.68) compared to placebo, with no major side effects reported in any study.[4] PEA has been described as a “promising alternative to chronic opioid analgesics, potentially reducing the risk of opioid abuse and dependency.”[1]

Unlike many conventional pain medications, PEA does not cause sedation, cognitive impairment, dependence, or significant gastrointestinal side effects. It works best as an “add-on” therapy to enhance the effects of other treatments.[5][6]

2. DIETARY SOURCES

PEA is found naturally in various foods:

Egg yolk: One of the richest sources
Soy lecithin: High concentration
Peanuts/peanut meal: Originally isolated from peanut oil
Corn: Contains measurable amounts
Soybeans: Good plant source
Tomatoes: Contains PEA
Peas: Moderate amounts
Milk and dairy products: Small amounts[3][7][8]

Important Bioavailability Note: Dietary sources provide only small amounts of PEA, far below therapeutic doses. Native (non-micronized) PEA is a large particle size lipid molecule with low solubility and poor bioavailability.[5][9] Micronization and ultramicronization techniques reduce particle size, dramatically improving absorption. A 2025 pharmacokinetic study found that water-dispersible PEA achieved 16 times higher total absorption (AUC) compared to non-micronized PEA.[10] Ultramicronized PEA (um-PEA) has been shown to efficiently cross the intestinal wall and, importantly, the blood-brain and blood-spinal cord barriers.[5][11]

3. INDICATIONS FOR NUTRACEUTICAL SUPPLEMENTATION

Pain Conditions with Moderate to High Quality Evidence:

Chronic Pain (General) – Moderate-High Quality Evidence

A 2025 meta-analysis (18 RCTs, 1,196 patients) confirmed PEA effectively reduces pain at 6 weeks (SMD = -0.9), 8 weeks (SMD = -0.98), and 24–26 weeks (SMD = -1.16)[1]
A 2023 meta-analysis (11 double-blind RCTs, 774 patients) found PEA reduced pain scores with SMD = 1.68 (p = 0.00001)[4]
A 2016 pooled meta-analysis showed PEA reduces pain by approximately 1 point every 2 weeks, with 81% of patients achieving pain score ≤3 by day 60[2]

Neuropathic Pain – Moderate Quality Evidence

Meta-analysis showed significant benefit for neuropathic pain (SMD = -0.97)[1]
Preclinical studies in diabetic peripheral neuropathy showed PEA reduced mechanical and thermal hyperalgesia, mast cell activation, and nerve damage[12]

Fibromyalgia – Moderate Quality Evidence

A 2024 pilot study (50 patients) found PEA 1,200 mg/day plus melatonin significantly improved pain, sleep, and quality of life[13]
A retrospective study of 407 fibromyalgia patients showed um-PEA reduced VAS pain scores from 75.8 to 52.5 (p0.001) and improved Fibromyalgia Impact Questionnaire scores[14]
A 2023 RCT found PEA + acetyl-L-carnitine added to duloxetine + pregabalin provided additional significant improvements in fibromyalgia outcomes[15]
A 2025 study found PEA + ALC significantly improved symptoms in fibromyalgia patients with small fiber involvement[16]

Nociplastic Pain – Low-Moderate Quality Evidence

A contemporary definition of “Nociplastic Pain” is “pain due to sensitization of the nervous system, without a sufficient underlying anatomical abnormality to explain the severity of pain. The basis of nociplastic pain is complex and poorly understood but it reflects changes in the functioning of pain processing like those that contribute to central sensitization.

1. Meta-analysis showed PEA effective for nociplastic pain )[1]

Musculoskeletal/Inflammatory Pain – Moderate Quality Evidence

Systematic review confirmed efficacy for nociceptive musculoskeletal pain)[1][17]
Low back pain, osteoarthritis, and other inflammatory conditions have shown benefit[17]

4. NUTRACEUTICAL’S IMPACT ON PAIN CONDITION

PEA addresses the underlying pathophysiology of chronic pain conditions through multiple mechanisms:

Mast Cell Regulation:
1. Down-modulates mast cell activation and degranulation[2][18][19]
2. Reduces release of inflammatory mediators (histamine, TNF-α, NGF) from mastells[20][18]
3. Mast cells are key players in neurogenic inflammation and pain sensitization

Glial Cell Modulation:
1. Controls microglial and astrocyte activation in the CNS[21][22][18]
2. Shifts microglia from pro-inflammatory (M1) to anti-inflammatory (M2) phenotype[21]
3. Reduces glial-mediated neuroinflammation that maintains chronic pain[2]

Nerve Protection and Regeneration:
1. Provides neuroprotection against oxidative and inflammatory damage[12][23]
2. Supports nerve fiber integrity and function
3. Reduces nerve growth factor (NGF) overexpression that contributes to pain[20][12]

5. NUTRACEUTICAL’S IMPACT ON PAIN PROCESSING

Pain processing refers to how pain signals are processed from the initial damaged tissue source of pain through the nerves and spinal cord to the brain and then down the spinal cord again. Nutraceuticals offer potential benefit for reducing the severity of the pain experience by acting at various levels of pain processing. These benefits are independent of the benefits the nutraceutical offers at the source of pain.

Level 1: Peripheral Pain Receptor (“Nociception Transduction”)

PEA modulates pain at the very first step—where nociceptors convert tissue damage into electrical signals:

Activates CB1 and TRPV1 receptors on sensory neurons, modulating nociceptor sensitivity[20]
Reduces local mast cell degranulation that sensitizes peripheral pain receptors[20][18]
Decreases NGF release, which normally increases nociceptor excitability[20]
Reduces local inflammatory mediators (TNF-α, prostaglandins) that activate nociceptors[20]

Level 2: Primary Afferent Transmission to Spinal Cord

PEA supports healthy signal transmission along peripheral nerves:

Protects peripheral nerve fibers from inflammatory and oxidative damage[12]
Reduces myeloperoxidase activity, indicating decreased inflammatory cell infiltration[24]
Supports nerve conduction by maintaining nerve fiber integrity
Reduces neurotrophic factor dysregulation that contributes to abnormal signaling[20]

Level 3: Spinal Cord Dorsal Horn Processing (First Synapse)

PEA has significant effects at the spinal cord level where pain signals are first processed:

Ultramicronized PEA crosses the blood-spinal cord barrier to act directly in the spinal cord[5][11]
Reduces spinal cord inflammatory pathways (NF-κB, phospho-P38 MAPK)[12]
Inhibits spinal microglia activation (reduced IBA-1 expression)[12]
Decreases spinal oxidative and nitrosative stress[11]
Reduces spinal cytokine release[12]

Level 4: Ascending Spinal Pathways and Supraspinal Processing

PEA crosses the blood-brain barrier to affect higher pain processing centers:

Modulates microglial activation in supraspinal structures[21][22]
Increases CB2 receptor expression through PPAR-α activation, enhancing endocannabinoid signaling[22]
Reduces neuroinflammation in brain regions involved in pain processing[25]
Decreases pro-inflammatory cytokines (TNF-α, IL-1β) in CNS tissues[25][26]

Level 5: Brain Cortical Processing and Pain Perception

PEA modulates the conscious experience of pain through:

Neuroprotective effects in cortical regions[8][19]
Modulation of neurotransmitter systems (dopamine, GABA) in brain areas associated with emotional processing[25]
Reduction of anxiety-like behavior associated with chronic pain[25]
Support of cognitive function and reduction of pain-related fatigue[19]

Level 6: Descending Pain Modulation

PEA supports the brain’s ability to inhibit pain signals:

Increases brain-derived neurotrophic factor (BDNF) expression[19]
Modulates hypothalamic-pituitary-adrenal (HPA) axis activity[25]
Supports GABAergic transmission in descending inhibitory pathways[25]
Reduces neuroinflammation in brainstem nuclei that control descending modulation[25]

Clinical Evidence for Effects on Pain Processing:

A randomized, double-blind, placebo-controlled crossover trial in healthy volunteers demonstrated that PEA (1,200 mg/day for 4 weeks) significantly:[27]

Decreased repetitive heat pain (peripheral sensitization marker)
Prolonged cold pain tolerance
Increased pressure pain tolerance
Decreased wind-up ratio (central sensitization marker)
Reduced area of allodynia (central sensitization marker)
Improved conditioned pain modulation (descending modulation marker)

6. BENEFITS FOR PAIN SENSITIZATION

Peripheral Sensitization: MODERATE-HIGH Quality Evidence

PEA reduces peripheral sensitization through:

Down-regulation of mast cell activation and degranulation[2][20][18]
Reduction of peripheral inflammatory mediators (TNF-α, NGF, prostaglandins)[20][12]
Modulation of CB1 and TRPV1 receptors on sensory neurons[20]
Protection of peripheral nerve fibers from inflammatory damage[12]
Clinical trial evidence showing decreased heat pain sensitivity and increased pain tolerance[27]

Central Sensitization: MODERATE-HIGH Quality Evidence

PEA addresses central sensitization through:

Crosses the blood-brain and blood-spinal cord barriers (especially ultramicronized forms)[5][11]
Inhibits spinal cord microglial and astrocyte activation[12][21]
Reduces spinal NF-κB and MAPK inflammatory pathways[12]
Decreases spinal oxidative stress[11]
Upregulates CB2 receptors through PPAR-α activation[22]
Clinical trial evidence showing decreased wind-up ratio and reduced allodynia area[27]
Improved conditioned pain modulation (descending inhibition)[27]

7. NUTRACEUTICAL’S IMPACT ON THE 4 DRIVING FORCES OF CHRONIC PAIN

1. Systemic Inflammation: STRONG EFFECT

PEA reduces systemic inflammation through:

Activation of PPAR-α, which inhibits NF-κB signaling[6]
Reduction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)[6][25]
Down-modulation of mast cell activation[2][18]
Reduction of serum inflammatory mediators (MCP-1, LPS)[25]
Modulation of immune cell function[3]

2. Neuroinflammation: STRONG EFFECT (Primary Mechanism)

This is one of PEA’s primary mechanisms of action:

Crosses the blood-brain and blood-spinal cord barriers[5][11]
Inhibits microglial activation and promotes M2 (anti-inflammatory) phenotype[21][22]
Reduces astrocyte activation (decreased GFAP expression)[12][19]
Inhibits mast cell infiltration and degranulation in CNS[19]
Decreases neuroinflammatory cytokines in brain and spinal cord[12][25]
Reduces spinal cord NF-κB and MAPK inflammatory pathways[12].

3. Oxidative Stress: MODERATE EFFECT

PEA reduces oxidative stress through:

Activation of Akt and ERK1/2 neuroprotective kinase pathways[23]
Reduction of reactive oxygen species (ROS) production[26][28]
Decreased lipid peroxidation in nerve tissue[19][28]
Reduction of protein nitrosylation and iNOS induction[19]
Protection against oxidative damage in neurons[23]

4. Mitochondrial Dysfunction: MODERATE EFFECT

PEA supports mitochondrial function through:

Modulation of mitochondrial oxidative capacity and energy efficiency[29]
Activation of AMPK pathway, supporting metabolic homeostasis[29]
Improvement of complex-I respiration rate and ATP content in cortical mitochondria[30]
Reduction of mitochondrial dysfunction in metabolically stressed cells[29]
PPAR-α-dependent counteraction of inflammation and mitochondrial dysfunction[25]

8. DOSING, TIMING, DURATION AND ADMINISTRATION

Recommended Dosing:

Chronic pain (general)

1. Dose: 600–1,200 mg
2. Frequency: Divided 2–3 times daily
3. Duration: Minimum 60 days

|Fibromyalgia

1. Dose: 1,200 mg
2. Frequency; 600 mg twice daily
3. Duration: Minimum 3 months

Neuropathic pain

1. Dose: 600–1,200 mg
2. Frequency: 600 mg twice daily
3. Duration: Minimum 60 days

Add-on to other analgesics

1. Dose: 300–600 mg
2. Frequency: 2–3 times daily
3. Duration: Ongoing

Key Dosing Points:

Most clinical trials used 600 mg twice daily (1,200 mg/day) or 400 mg three times daily[27][13]
A 2024 meta-analysis found that extended treatment (≥60 days) provides significantly greater pain relief than 30 days—an additional 1.36 points on pain scales[31]
Pain reduction is time-dependent: approximately 35% reduction in the first month, followed by an additional 35% reduction in the second month[31]
The optimal dose range for absorption appears to be 300–600 mg per dose[9]

Timing:

Can be taken with or without food
Divide total daily dose into 2–3 doses throughout the day
No specific timing requirements

Duration of Onset:

Early effects: Some improvement may be noticed within 2–4 weeks[1]
Meaningful improvement: Typically 4–6 weeks for significant pain reduction[1]
Optimal effects: 60+ days for full therapeutic benefit[31]
Progressive improvement: Pain continues to decrease with longer treatment duration[2][31]

9. FORMULATION CONSIDERATIONS

Particle Size Matters:

Native (non-micronized) PEA has poor oral bioavailability due to its lipophilic nature and large particle size. Micronization dramatically improves absorption and efficacy:[5][24]

Micronized PEA (PEA-m): Particle size ~10 μm; improved absorption
Ultramicronized PEA (um-PEA): Particle size ~6 μm or smaller; superior absorption and CNS penetration
Water-dispersible PEA: Newest formulation with up to 16-fold higher absorption than non-micronized PEA[10]

Clinical Evidence for Formulation Superiority:

A preclinical study demonstrated that micronized and ultramicronized PEA significantly reduced inflammation and hyperalgesia when given orally, while non-micronized PEA at the same dose was ineffective.[24] Ultramicronized PEA has been shown to efficiently cross the blood-brain and blood-spinal cord barriers.[5]

Combination Formulations:

PEA + Luteolin: Antioxidant flavonoid combination for enhanced neuroprotection[32]
PEA + Polydatin: Stilbene antioxidant combination[32]
PEA + Melatonin: For pain with sleep disturbance[13]
PEA + Acetyl-L-carnitine: Synergistic combination for neuropathic and inflammatory pain[33][15]

Quality Considerations:

Choose micronized or ultramicronized formulations for optimal efficacy
Look for products from reputable manufacturers with quality certifications
Avoid non-micronized/native PEA products for oral use

10. SYNERGIES WITH OTHER PAIN MEDICATIONS AND NUTRACEUTICALS

Nutraceuticals:

Acetyl-L-carnitine (ALC): A 1:1 combination of um-PEA and ALC showed superior anti-inflammatory and anti-nociceptive effects compared to either alone. A clinical trial found PEA + ALC added to standard fibromyalgia treatment provided additional significant improvements.[33][15][16]
Alpha-lipoic acid: Complementary antioxidant and mitochondrial support
Luteolin: Antioxidant flavonoid that enhances PEA’s neuroprotective effects[32]
Polydatin: Stilbene antioxidant with synergistic effects[32]
Melatonin: Combination improved pain, sleep, and quality of life in fibromyalgia[13]

Conventional Medications:

Opioids (morphine, tramadol): PEA synergistically enhances opioid antinociception, potentially allowing lower opioid doses. PEA may also limit opioid tolerance development.[5][34][35]
Gabapentin/Pregabalin: PEA synergizes with gabapentin’s antinociceptive effects through PPAR-α and opioid receptor mechanisms[15][34]
Duloxetine: PEA + ALC added to duloxetine + pregabalin provided additional benefits in fibromyalgia[15]
Paracetamol (acetaminophen): um-PEA + paracetamol combination showed synergistic pain relief through NF-κB pathway inhibition[36]
NSAIDs: Complementary anti-inflammatory mechanisms

11. DRUG INTERACTIONS

No Significant Drug Interactions Identified:

PEA has an excellent safety profile with no known clinically significant drug interactions.[3][37][38] This is one of its major advantages over conventional pain medications.

Theoretical Considerations:

PEA is metabolized by fatty acid amide hydrolase (FAAH) and N-acylethanolamine-hydrolyzing acid amidase (NAAA)[37]
No interactions with cytochrome P450 enzymes have been reported
PEA does not affect warfarin, diabetes medications, or other common drugs

Safe Combinations:

Can be safely combined with opioids, gabapentinoids, antidepressants, and NSAIDs[5][15]
No dose adjustments needed when combining with other medications
Enhances efficacy of many analgesics without increasing side effects[5][6]

Always inform your healthcare provider about all supplements you take.

12. SAFETY AND CONTRAINDICATIONS

Excellent Safety Profile: Multiple systematic reviews and meta-analyses confirm that PEA is well-tolerated and devoid of significant side effects in both animals and humans.[4][3][38]

A 2016 review of clinical trials found no serious adverse drug reactions at an incidence of 1/200 or greater for treatment up to 49 days[38]
A 2023 meta-analysis reported “no major side effects were attributed to PEA in any study”[4]
A 2025 review confirmed “good safety and tolerability” across various pain conditions[6]

Possible Side Effects (rare and usually mild):

Gastrointestinal symptoms: diarrhea, dyspepsia, bloating, constipation (reported in ~14% of fibromyalgia patients in one study)[14]
These effects are generally mild and transient

Contraindications:

Known allergy to PEA or related compounds
Pregnancy and breastfeeding (insufficient safety data, though no adverse effects have been reported)

Who Should Use Caution:

Patients with severe liver disease (PEA is metabolized in the liver)
Those with known allergies to peanuts or soy (PEA was originally isolated from these sources, though purified supplements should not contain allergens)

13. SPECIAL CONSIDERATIONS / TIPS

Formulation is critical: Choose micronized or ultramicronized PEA for optimal absorption and efficacy
Be patient: Allow 4–8 weeks for meaningful improvement; benefits continue to increase with longer treatment
Extended treatment: A minimum of 60 days is recommended for optimal pain relief[31]
Add-on therapy: PEA works best when added to existing pain treatments, not as a replacement[5]
Consistent dosing: Take regularly throughout the day for best results
Quality products: Choose reputable brands with third-party testing
Combination products: Consider formulations with luteolin, ALC, or other synergistic compounds
No tolerance or dependence: Unlike opioids, PEA does not cause tolerance, dependence, or withdrawal[1]
No cognitive effects: PEA does not cause sedation or cognitive impairment
Opioid-sparing potential: PEA may allow reduction of opioid doses when used in combination[5][35]

14. COSTS

Standard micronized PEA (600 mg capsules): $25–45 per month (at 1,200 mg/day)
Ultramicronized PEA: $35–60 per month
Combination products (PEA + luteolin, PEA + ALC): $40–70 per month
Water-dispersible PEA: $45–75 per month

PEA is available as a dietary supplement or “food for special medical purposes” depending on the country. It is generally affordable compared to many prescription pain medications and has no significant drug interactions that would require additional monitoring costs.

Remember: PEA works best as part of a comprehensive pain management plan that includes proper medical care, physical activity, stress management, and healthy nutrition. PEA is particularly valuable as an “add-on” therapy to enhance the effects of other treatments while potentially reducing the need for higher doses of conventional medications. Its excellent safety profile makes it suitable for long-term use. Always discuss any new supplement with your healthcare provider before starting.

References

Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Viña I, López-Moreno M. Nutrition Reviews. 2025;83(7):e1604-e1618. doi:10.1093/nutrit/nuae203.
Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-Analysis. Paladini A, Fusco M, Cenacchi T, et al. Pain Physician. 2016;19(2):11-24.
Palmitoylethanolamide: A Natural Compound for Health Management. Clayton P, Hill M, Bogoda N, Subah S, Venkatesh R. International Journal of Molecular Sciences. 2021;22(10):5305. doi:10.3390/ijms22105305.
Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Lang-Illievich K, Klivinyi C, Lasser C, et al. Nutrients. 2023;15(6):1350. doi:10.3390/nu15061350.
Ultramicronized N-Palmitoylethanolamine Associated With Analgesics: Effects Against Persistent Pain. Nobili S, Micheli L, Lucarini E, et al. Pharmacology & Therapeutics. 2024;258:108649. doi:10.1016/j.pharmthera.2024.108649.
Palmitoylethanolamide in the Treatment of Pain and Its Clinical Application Prospects. Wang Y, Duan X, Li Z, Pan Y, Deng J. Drug Design, Development and Therapy. 2025;19:6897-6923. doi:10.2147/DDDT.S540327.
Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy With Different Antioxidant Molecules Present in Diets. Peritore AF, Siracusa R, Crupi R, Cuzzocrea S. Nutrients. 2019;11(9):E2175. doi:10.3390/nu11092175.
Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease. Beggiato S, Tomasini MC, Ferraro L. Frontiers in Pharmacology. 2019;10:821. doi:10.3389/fphar.2019.00821.
Palmitoylethanolamide as a Supplement: The Importance of Dose-Dependent Effects for Improving Nervous Tissue Health in an in Vitro Model. Galla R, Mulè S, Ferrari S, et al. International Journal of Molecular Sciences. 2024;25(16):9079. doi:10.3390/ijms25169079.
Pharmacokinetics of Micronized and Water Dispersible Palmitoylethanolamide in Comparison With Standard Palmitoylethanolamide Following Single Oral Administration in Male Sprague-Dawley Rats. Mehkri S, Dinesh KG, Ashok G, Bopanna K. Indian Journal of Pharmacology. 2025;57(4):219-225. doi:10.4103/ijp.ijp_964_24.
Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-Hyperalgesic Effect. Petrosino S, Cordaro M, Verde R, et al. Frontiers in Pharmacology. 2018;9:249. doi:10.3389/fphar.2018.00249.
The Neuroprotective Effects of Micronized PEA (PEA-m) Formulation on Diabetic Peripheral Neuropathy in Mice. Impellizzeri D, Peritore AF, Cordaro M, et al. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2019;33(10):11364-11380. doi:10.1096/fj.201900538R.
A Fixed Combination of Palmitoylethanolamide and Melatonin (PEATONIDE) for the Management of Pain, Sleep, and Disability in Patients With Fibromyalgia: A Pilot Study. Terribili R, Vallifuoco G, Bardelli M, Frediani B, Gentileschi S. Nutrients. 2024;16(16):2785. doi:10.3390/nu16162785.
Ultramicronized Palmitoylethanolamide (Um-Pea) as Add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients. Schweiger V, Martini A, Bellamoli P, et al. CNS & Neurological Disorders Drug Targets. 2019;18(4):326-333. doi:10.2174/1871527318666190227205359.
Palmitoylethanolamide and Acetyl-L-Carnitine Act Synergistically With Duloxetine and Pregabalin in Fibromyalgia: Results of a Randomised Controlled Study. Salaffi F, Farah S, Sarzi-Puttini P, Di Carlo M. Clinical and Experimental Rheumatology. 2023;41(6):1323-1331. doi:10.55563/clinexprheumatol/pmdzcq.
Retrospective Evaluation of L-Acetyl Carnitine and Palmitoylethanolamide as Add-on Therapy in Patients With Fibromyalgia and Small Fiber Neuropathy. Bentivenga C, Cicero AFG, Fogacci F, et al. Pharmaceutics. 2025;17(8):1004. doi:10.3390/pharmaceutics17081004.
Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence. Scuteri D, Guida F, Boccella S, et al. Pharmaceutics. 2022;14(8):1672. doi:10.3390/pharmaceutics14081672.
Glia and Mast Cells as Targets for Palmitoylethanolamide, an Anti-Inflammatory and Neuroprotective Lipid Mediator. Skaper SD, Facci L, Giusti P. Molecular Neurobiology. 2013;48(2):340-52. doi:10.1007/s12035-013-8487-6.
Therapeutic Effect of Palmitoylethanolamide in Cognitive Decline: A Systematic Review and Preliminary Meta-Analysis of Preclinical and Clinical Evidence. Colizzi M, Bortoletto R, Colli C, et al. Frontiers in Psychiatry. 2022;13:1038122. doi:10.3389/fpsyt.2022.1038122.
The Endogenous Fatty Acid Amide, Palmitoylethanolamide, Has Anti-Allodynic and Anti-Hyperalgesic Effects in a Murine Model of Neuropathic Pain: Involvement of CB(1), TRPV1 and PPARgamma Receptors and Neurotrophic Factors. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. Pain. 2008;139(3):541-550. doi:10.1016/j.pain.2008.06.003.
Palmitoylethanolamide Modulation of Microglia Activation: Characterization of Mechanisms of Action and Implication for Its Neuroprotective Effects. D’Aloia A, Molteni L, Gullo F, et al. International Journal of Molecular Sciences. 2021;22(6):3054. doi:10.3390/ijms22063054.
Palmitoylethanolamide Induces Microglia Changes Associated With Increased Migration and Phagocytic Activity: Involvement of the CB2 Receptor. Guida F, Luongo L, Boccella S, et al. Scientific Reports. 2017;7(1):375. doi:10.1038/s41598-017-00342-1.
The Neuroprotective Properties of Palmitoylethanolamine Against Oxidative Stress in a Neuronal Cell Line. Duncan RS, Chapman KD, Koulen P. Molecular Neurodegeneration. 2009;4:50. doi:10.1186/1750-1326-4-50.
Micronized/Ultramicronized Palmitoylethanolamide Displays Superior Oral Efficacy Compared to Nonmicronized Palmitoylethanolamide in a Rat Model of Inflammatory Pain. Impellizzeri D, Bruschetta G, Cordaro M, et al. Journal of Neuroinflammation. 2014;11:136. doi:10.1186/s12974-014-0136-0.
Palmitoylethanolamide Dampens Neuroinflammation and Anxiety-Like Behavior in Obese Mice. Lama A, Pirozzi C, Severi I, et al. Brain, Behavior, and Immunity. 2022;102:110-123. doi:10.1016/j.bbi.2022.02.008.
Chronic Oral Palmitoylethanolamide Administration Rescues Cognitive Deficit and Reduces Neuroinflammation, Oxidative Stress, and Glutamate Levels in a Transgenic Murine Model of Alzheimer’s Disease. Beggiato S, Tomasini MC, Cassano T, Ferraro L. Journal of Clinical Medicine. 2020;9(2):E428. doi:10.3390/jcm9020428.
The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-a Randomized, Double-Blinded, Placebo-Controlled Crossover Trial. Lang-Illievich K, Klivinyi C, Rumpold-Seitlinger G, Dorn C, Bornemann-Cimenti H. Nutrients. 2022;14(19):4084. doi:10.3390/nu14194084.
Oxyhomologation of the Amide Bond Potentiates Neuroprotective Effects of the Endolipid N-Palmitoylethanolamine. Lombardi G, Miglio G, Varsaldi F, Minassi A, Appendino G. The Journal of Pharmacology and Experimental Therapeutics. 2007;320(2):599-606. doi:10.1124/jpet.106.112987.
Palmitoylethanolamide Counteracts Hepatic Metabolic Inflexibility Modulating Mitochondrial Function and Efficiency in Diet-Induced Obese Mice. Annunziata C, Lama A, Pirozzi C, et al. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2020;34(1):350-364. doi:10.1096/fj.201901510RR.
Effects of Ultramicronized Palmitoylethanolamide on Mitochondrial Bioenergetics, Cerebral Metabolism, and Glutamatergic Transmission: An Integrated Approach in a Triple Transgenic Mouse Model of Alzheimer’s Disease. Bellanti F, Bukke VN, Moola A, et al. Frontiers in Aging Neuroscience. 2022;14:890855. doi:10.3389/fnagi.2022.890855.
Extended Treatment With Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis. Schweiger V, Schievano C, Martini A, et al. Nutrients. 2024;16(11):1653. doi:10.3390/nu16111653.
The Pharmacology of Palmitoylethanolamide and First Data on the Therapeutic Efficacy of Some of Its New Formulations. Petrosino S, Di Marzo V. British Journal of Pharmacology. 2017;174(11):1349-1365. doi:10.1111/bph.13580.
Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-L-Carnitine on Experimental Model of Inflammatory Pain. Ardizzone A, Fusco R, Casili G, et al. International Journal of Molecular Sciences. 2021;22(4):1967. doi:10.3390/ijms22041967.
N-Palmitoylethanolamide Synergizes the Antinociception of Morphine and Gabapentin in the Formalin Test in Mice. Déciga-Campos M, Jaramillo-Morales OA, Espinosa-Juárez JV, et al. The Journal of Pharmacy and Pharmacology. 2023;75(9):1154-1162. doi:10.1093/jpp/rgad004.
N-Palmitoylethanolamide Enhances Antinociceptive Effect of Tramadol in Neuropathic Rats. Alejo-Martínez A, Bravo G, López-Muñoz FJ. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2025;182:117760. doi:10.1016/j.biopha.2024.117760.
Ultramicronized Palmitoylethanolamide and Paracetamol, a New Association to Relieve Hyperalgesia and Pain in a Sciatic Nerve Injury Model in Rat. Peritore AF, Siracusa R, Fusco R, et al. International Journal of Molecular Sciences. 2020;21(10):E3509. doi:10.3390/ijms21103509.
The Basal Pharmacology of Palmitoylethanolamide. Rankin L, Fowler CJ. International Journal of Molecular Sciences. 2020;21(21):E7942. doi:10.3390/ijms21217942.
Palmitoylethanolamide for the Treatment of Pain: Pharmacokinetics, Safety and Efficacy. Gabrielsson L, Mattsson S, Fowler CJ. British Journal of Clinical Pharmacology. 2016;82(4):932-42. doi:10.1111/bcp.13020.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.